



Corporate Deck

公司报告

October 2023
2023年10月

Statements in this document may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as “expects,” “anticipates,” “intends,” “plans,” “aims,” “targets,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” “suggests,” “could,” “would,” “should,” “may,” “will” and similar expressions identify forward-looking statements. These forward-looking statements relate to the timing, completion and delivery of data from clinical studies, the effectiveness of Volition’s blood-based diagnostic and prognostic tests as well as Volition’s ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic or prognostic tool for COVID-19. Volition’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic or prognostic products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition’s failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition’s development pipeline or any other diagnostic or prognostic products Volition might develop; Volition’s failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition’s intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; downturns in domestic and foreign economies; and other risks identified in Volition’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to “\$” refer to the legal currency of the United States of America.

- Diagnostic company focusing on epigenetic markers / 专注于表观遗传学市场的诊断公司
 - Epigenetics = on top of, or in addition to the genome / 表观遗传学 = 在基因组之上，或在基因组之外
- Human and Veterinary use cases: / 人体和兽用：
 - Screening / 筛查
 - Monitoring (disease progression and response to treatment) / 监测（疾病进展和治疗效果）
- We believe our TOTAL addressable markets are significant \$70 billion TAM¹ / 我们认为我们产品的潜在市场规模高达\$700亿¹
- Two key product areas anticipated in the short term (2023-2024): / 预计短期内(2023-2024)两个主要产品
 - Vet Cancer / 动物癌症
 - Sepsis / 败血症

Global supply & licensing agreements signed. / 签署了全球供应与许可协议

1. VNRX TAM Model (Vet, NETs, Cancer, Discover)

What sets us apart? / 我们的独特之处

- Our tests are *simple, low-cost accessible* routine blood tests / 我们的检测简单、便宜、方便
 - Platform agnostic, can be adapted to any diagnostic workflow / 诊断平台适用于任何诊断工作流程
 - Manual, Reference Lab, Specialist Lab and Point of Care / 手动、大型实验室、专业实验室和护理点




Six Hours /
六个小时



45 minutes
/ 45分钟



<10 minutes
/ 低于10分钟



20 minutes
/ 20分钟




<15 minutes /
不到15分钟

- Our *Intellectual Property* / 我们的知识产权
 - 95 patents granted, 126 pending, across 46 patent families worldwide¹ / 已获得95项专利，待批126项专利，覆盖全球46个专利家族¹

How does the Nu.Q[®] Test work? / Nu.Q[®]检测如何进行? Volition

The Nu.Q[®] Test is a proprietary epigenetic immunoassay platform that determines levels of circulating nucleosomes in the blood. / Nu.Q[®]检测是一种专有的表观遗传免疫测定平台，可确定血液中循环核小体的水平



Product Pillars / 支柱产品

Powered by / 驱动力是 

nu·Q
vet

nu·Q
nets

nu·Q
discover

nu·Q
cancer



nu·Q
capture

TAM¹

\$11B /

\$110亿

2023

TAM¹

\$22B /

\$220亿

2024/25

TAM¹

\$600M /

\$6亿

2023

1. VNRX TAM Model (Vet, NETs, Discover)



Nu.Q® Vet Cancer Test / Nu.Q®动物癌症检测

Number of pet dogs in the U.S. ¹ / 美国宠物狗的数量¹



**Approximately
84 million /
大约8400万**



Dogs Diagnosed with Cancer Annually / 每年诊 断出癌症的狗²

Volition 



**Approximately
6 million
/ 约600万**



Nearly 50%

Of dogs over the age of 10 will
develop cancer³ / 10岁以上的
狗中50%将患有癌症³




Early Detection

Can lead to improved treatment outcomes /
早诊断可以治疗效果提升

1. Larkin, M. (2021). Pet population still on the rise, with fewer pets per household. AVMA. Retrieved 7/9/22 .
2. COP - Pet Owners - What is Comparative Oncology. Ccr.cancer.gov. Retrieved 7/9/22
3. AVMA - <https://www.avma.org/resources/pet-owners/petcare/cancer-pets> Retrieved Jan 23

Nu.Q® Vet TAM \$11 Billion for canine and feline cancer screening & monitoring¹ / Nu.Q®用于犬科动物和猫科动物筛查与监测的潜在市场规模¹



Total Annual Accessible Market \$11 Billion / 潜在市场规模总计\$110亿

1. VNRX TAM Model

Our Current Product Proposition / 我们当前产品的定位



- The **Nu.Q® Vet Cancer Test** is positioned for use in the annual health check of older dogs (those that are seven years and older) and may also be a complementary test for younger dogs at high risk for developing cancer in their lifetimes, such as **Golden Retrievers** / **Nu.Q®动物癌症筛查检测**被定位为用于老年狗（7岁及以上）的年度健康检查，也可以是对金毛寻回犬等一生中患癌风险较高的年轻狗的一种补充检测。
- It is a **simple, low-cost, easy to use** ELISA based screening blood test which will help streamline the diagnostic process / 它是一种简单、低成本、方便使用的基于ELISA的血液筛查检测，将有助于简化诊断过程。

Peer Reviewed Published Data¹ / 同行评审发表的数据¹

Number of Dogs with Cancer / 患癌狗的数量	528
Number of Healthy Dogs / 健康狗的数量	134
Specificity / 特异性	97%
Detection of Hemangiosarcoma / 检测到血管肉瘤	82%
Detection of Lymphoma / 检测到淋巴瘤	77%
Detection of Systemic Cancers / 检测到全身性癌症	76%

Accessible, Affordable, Reliable, Rapid / 方便、经济、可靠、快速

1. Wilson-Robles, H.M., Bygott, T., Kelly, T.K. et al. Evaluation of plasma nucleosome concentrations in dogs with a variety of common cancers and in healthy dogs. BMC Vet Res 18, 329 (2022).

What happens if there is a positive result? / 如果结果为阳性，该怎么办？

- A discussion between the veterinarian and the pet owner. Assess age, breed etc. / 兽医与宠物主人讨论，评估年龄、品种等
- Pursue additional diagnostic testing to help identify the location & type of cancer / 进行更多的诊断测试以帮助确定癌症位置和类型
- E.g., ultrasound, CT scan, radiographs, blood work, tissue sample biopsy. / 例如超声波、CT扫描、X光照片、血液检测、组织标本活检

Common Cancers frequently detected by the Nu.Q® Vet Cancer Test are Lymphoma, Hemangiosarcoma and Histiocytic Sarcoma - Use of chemotherapeutics standard and most successful in treating these cases. / Nu.Q®动物癌症检测经常检测到的**常见癌症**有淋巴瘤、血管肉瘤和组织细胞肉瘤 - 化疗是治疗这些病例的标准方法，也是最成功的方法。

How can EARLY detection help the dog and pet owner? / 早诊断如何帮助狗和宠物主人？

- Nu.Q® is positioned for use in healthy dogs. / Nu.Q®适用于健康的狗
- Treating “healthy” animals for disease prior to them becoming sick provides improved longer-term results and treating early also saves money. / 在“健康”的动物生病之前对其进行治疗，可获得更好的长期效果，而且早期治疗还能节省资金
- Opens up opportunities for therapeutic product development to pharmaceutical companies. / 为制药公司提供治疗产品开发的机会

Lymphoma Monitoring

淋巴瘤检测



Hot-off-the-Press!! /
最新新闻!!

Peer reviewed paper
published May 2023 /
同行评审，2023年5月发
布的论文



NEW
Indication! /
新适应症!


Lymphoma Monitoring Application

淋巴瘤检测应用




- ❧ Can be a useful tool for: / 可以用于:
 - ❧ monitoring disease progression, / 监测疾病进展
 - ❧ monitoring treatment response / 监测治疗反应
 - ❧ Monitoring when a dog goes into / comes out of remission. / 监测狗的病情缓解和恢复情况
- ❧ When used appropriately is a valuable addition to the veterinary oncology toolbox. / 如果使用得当，它将成为兽医肿瘤学工具箱中的重要补充
- ❧ Simple, routine, low-cost blood test. / 简单、常规、低成本的血液检测

Global Reach: Today / 目前在全球市场的布局



Global Reach Targets: Q4 2023 / 全球布局目标: 2023年第四季度



Development Pipeline / 开发管线

Cancer in
Cats / 猫的
癌症

NETosis

Elite
Equestrian
/ 精英骑马

Production
Animals /
生产动物




**Sepsis &
Thrombosis /
败血症与血栓症**

NETs – a recent breakthrough in medical science

/ 医学新突破

Neutrophil Extracellular Traps (NETs): / 中性粒细胞胞外陷阱(NETs):

- are produced by ejecting chromosomal material out of the cell / 是通过将染色体材料排出细胞而产生的
- catch and kill bacteria and viruses / 捕捉并杀死细菌和病毒
- can sterilize blood in minutes / 可在几分钟内对血液进行消毒




Picture from / 图片来自
[Why Immune Cells Extrude Webs of DNA and Protein, The Scientist, Oct 1, 2019](#)

Bacteria
and viruses
细菌与病毒



Neutrophil
(white blood cell)

嗜中性粒细胞
(白细胞)



Nucleosome
核小体

Neutrophil
extracellular trap (NET)

中性粒细胞胞外陷阱

NETs have a dark side... / NETs也有阴暗面...

Recent studies have pointed to the pivotal role of NETs release in the progression of certain acute, chronic debilitating and fatal conditions: /最近的研究表明，NETs 的释放在某些急性、慢性衰弱和致命疾病的发展过程中起着关键作用：

- Sepsis / 败血症
- Severe trauma / 严重创伤
- Thrombosis / 血栓症
- Metastatic Cancer / 转移性癌症
- COVID-19 / 新冠病毒
- Transplant Organ viability and Rejection / 移植器官的生存能力和排斥反应
- Kidney Dialysis complications / 肾透析并发症
- Diabetes complications (eg; foot amputation) / 糖尿病并发症（例如，足部截肢）
- Multiple Sclerosis / 多发性硬化症
- Sickle Cell Disease / 镰状细胞贫血症


Source: Santerus AG Corporate Deck May 2022

Sepsis places heavy health, social & economic burden / 败血症造成沉重的健康、社会和经济负担



Almost 50M cases / 约5000万例¹
11M deaths / 1100万例死亡¹
42% children under 5 years of age¹ / 42%是五岁以下儿童

Economic burden of sepsis ~\$62 billion p.a. in the U.S alone & expected to increase² / 败血症带来的经济负担仅在美国就达到每年约620亿美元，预计会上升²



1. Sakr Y, Jaschinski U, Wittebole X, Szakmany T, Lipman J, Namendys-Silva SA, Martin-Loeches I, Leone M, Lupu MN, Vincent JL; ICON Investigators. Sepsis in Intensive Care Unit Patients: Worldwide Data From the Intensive Care over Nations Audit. Open Forum Infect Dis. 2018 Nov 19;5(12):ofy313. doi: 10.1093/ofid/ofy313. PMID: 30555852; PMCID: PMC6289022.

2. Rhee C, et al. Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data, 2009-2014. JAMA. 2017 Oct 3;318(13):1241.

3. The bar graphs provided by courtesy of Professor Djillali Annane / 柱状图由Djillali Annane教授提供

Sepsis – current challenges / 败血症 –当前的挑战

- The rapid identification and treatment of sepsis significantly improves patient outcomes and reduces complications and long-term morbidity¹. / 快速识别和治疗败血症可显著改善患者的预后，减少并发症和长期发病率¹
- **The risk of death from sepsis increases by 7.6% for each hour of delay in appropriate antibiotic therapy².** / 每延迟一小时接受适当的抗生素治疗，因败血症死亡的风险就会增加 **7.6%**²
- CURRENT methods of assessment (SOFA and APACHE II) are both complex & slow. / 目前的评估方法（SOFA 和 APACHE II）既复杂又缓慢

1.Singer, M., et al. (2016). The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 315(8), 801-810. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968574/>

2.Kumar, A.,et al. (2006). Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Critical care medicine, 34(6), 1589-1596.

Our focus... / 我们专注于



To develop a low cost, easy to use diagnostic test to **stratify risk** of sepsis particularly those at risk of progressing to multiple organ failure; in addition to **monitoring** the disease progression and response to treatment. / 开发一种成本低、使用方便的诊断测试，以对脓毒症风险进行分层，尤其是那些有可能发展为多器官衰竭的患者；此外，还能监测疾病的进展和对治疗的反应。


The Nu.Q® NETs assay: / Nu.Q® NETs化验:

- has demonstrated potential in the early detection of sepsis / 展示了具有早期检测败血症的潜力
- is manufactured to ISO13485 standard / 按照ISO13485标准制造
- is analytically validated, reliable, reproducible and rapidly available. / 经分析验证、可靠、可重复且可快速获得

Large studies now underway with KOLs at several Centers of Excellence. /

目前正在几个卓越中心与关键意见领袖开展大型研究

Our Building Blocks / 我们的积木



The story so far... / 目前的进展

**KOL
development**
/ 关键意见领袖
发展



**Centers of
excellence**
/ 卓越中心



**Major projects
underway at
seven leading EU
hospitals / 在七家
主要的欧盟医院进
行大型项目**

**Clinical
Evidence &
Publications**
/ 临床证据与
出版物




**2 clinical papers, 6
posters published to
date with more
expected in H2 2023 /
截止目前已经发布了2
篇临床论文和6篇海报，
预计2023年下半年将
有更多出版物发布**

Clinical Evidence / 临床证据


Published studies to date demonstrate the Nu.Q® NETs assay: / 截止目前出版的研究表明， Nu.Q® NETs化验：

- may be predictive at hospital admission of which patients with COVID-19 will develop sepsis requiring organ support in intensive care and which patients will be adequately cared for in a regular ward^{1,2} / 在入院时，可预测哪些COVID-19患者会出现败血症，需要在重症监护室接受器官支持，哪些患者可在普通病房得到充分护理^{1,2}.
- may be predictive at hospital admission of 28-day mortality due to COVID-19 sepsis² / 可预测入院时因 COVID-19 败血症导致的 28 天死亡率²
- correlates with the severity of sepsis¹⁻⁶ / 与败血症的严重程度有关¹⁻⁶.
- correlates with SOFA score and APACHE II score / 与SOFA分值和APACHE II 分值有关³⁻⁶



1. Cavalier E, et al (2021) Circulating Nucleosomes as Potential Markers to Monitor COVID-19 Disease Progression. *Front. Mol. Biosci.* 8:600881.
2. Rea C, et al. Circulating Nucleosome Immunoassay: Evaluating a Clinically-applicable Test to Risk Stratify COVID-19 and Target Anticoagulation [abstract]. *Res Pract Thromb Haemost.* 2021; 5 (Suppl 2).
3. Douxfils J, Morimont L, et al. Evaluation and comparison of NETosis biomarkers in sepsis and COVID-19 patients [abstract]
4. Morimont L, et al. NETosis and Nucleosome Biomarkers in Septic Shock and Critical COVID-19 Patients: An Observational Study. *Biomolecules.* 2022 Jul 27;12(8):1038. doi: 10.3390/biom12081038. PMID: 36008932; PMCID: PMC9405965.
5. Herzog M, et al (2022) Circulating Nucleosomes are Markers of NETosis and Correlate with SOFA scores in sepsis. *International Sepsis Forum 2022.*
6. Micallef J, et al (2023) Plasma Nucleosome Measurement as a biomarker for NETs in Intensive Care Patients. 42nd International Symposium on Intensive Care & Emergency Medicine. *Crit Care* 27 (Suppl 1), 119 (2023). <https://doi.org/10.1186/s13054-023-04377-x>

The story so far ctd... / 目前的进展（续）




Nu.Q® NETs Sepsis Annual TAM ~\$22 Billion¹

Nu.Q® NETs败血症每年潜在市场规模约\$220亿¹



TOTAL ANNUAL ADDRESSABLE MARKET, SEPSIS RISK STRATIFICATION & MONITORING, US\$
每年潜在市场规模，败血症风险分层与监测，美元



Annual Total Addressable Market ~\$22 Billion
每年潜在市场规模约为\$220亿

* Based on only two tests per patient /
基于每位患者仅进行两项测试

Source / 来源 : VNRX TAM Model



Commercial Strategy

商业化策略

Overall strategy / 总体策略

- R&D conducted by Volition and its research partners / Volition和其研究合作伙伴进行研发
- Volition monetizes IP by supplying key components (milestone payments and ongoing revenue) / Volition 通过提供关键组件实现知识产权变现（里程碑付款和持续收入）
- Commercialisation via global players and in fragmented markets, regional companies / 通过跨国企业进行商业化，在分散市场通过区域性公司进行商业化

Partner with established diagnostic companies to market, sell, and process our test / 与成熟的诊断公司合作进行营销、销售和我们的检测

- Leveraging their networks and expertise / 利用他们的网络和专长
- Multi-platform (external lab and point-of-care) / 多平台（外部实验室和护理点）
- Joint tech transfer / 联合技术转让

Two underlying principles: / 两个基本原则：

- **Low CapEx** for partners / **Low OpEx** for Volition / 合作伙伴资本开支低 / Volition运营开支低
- **Accessible** worldwide / 全球可及

Commercial Deals: August 2023 Update / 商业交易：2023年8月更新




- Signed a global supply agreement with a IDEXX Laboratories Inc. to provide test through worldwide reference lab network / 与IDEXX Laboratories Inc.签署全球供应协议，通过全球大型实验室网络提供检测**
 - Launched in the U.S. in Jan 2023. Other countries expected to roll out later in 2023 / 2023年1月在美国启动，其他国家在2023年晚些时候启动
- Signed up to \$28m + agreement with Heska / 与Heska签署价值\$2800万以上的协议**
 - Milestones (\$10m upfront, plus \$13m anticipated in the coming months and a further \$5m based upon the launch of the next products) / 里程碑（首付款\$1000万，未来数月预计增加\$1300万，基于下一个产品的启动再增加\$500万）
 - PLUS, ongoing revenue from the purchase of kits and key components / 加上，购买套装和关键零部件获得持续性收入
 - Scope: **companion animal, cancer, point of care (POC)**, or 10-15% of the market / 范围：宠物、癌症、护理点，或市场的10-15%
 - Launched via Heska's Veterinary Diagnostics Labs in the U.S. and EU. / 通过Heska在美国和欧盟的兽医诊断实验室启动
- Anticipate signing several other potential licensing and supply agreements and /or distribution partners for Nu.Q® Vet this year. / 预计今年将签署Nu.Q® Vet的另外几项潜在许可和供应协议以及/或分销合作伙伴**
- Negotiations underway with key players in the sepsis and thrombosis market for Nu.Q® NETs / 与败血症和血栓症市场主要公司针对Nu.Q® NETs正在进行协商**

Nu.Q® Vet Cancer Test Opportunity Simulation ¹

Nu.Q® Vet癌症检测机会模拟 ¹

Revenue Opportunity*
(\$millions) / 收入机会 (\$百万)

*Not revenue guidance and not indicative of the Reference Lab to POC market split & margin guidance. / 不是收入指引，也不表明大型实验室与护理点市场的划分和利润率指引



Number of Tests
检测数量

~ Underlying Burn Rate / 潜在的资金消耗率
(excluding milestone payments / 不包括里程碑付款)
\$27m in 2022 / 2022年\$2700万

1. VNRX TAM Model

Summary & Financial Update

总结与财务更新

Summary / 总结

- Diagnostic company focusing on epigenetic markers / 专注于表观遗传学市场的诊断公司
- Human and Veterinary use cases for screening & monitoring life altering diseases / 用于筛查和监测重大疾病的人体和兽医病例
- We believe our addressable markets are significant - \$70 billion TAM / 我们认为我们产品的潜在市场规模高达\$700亿
- Focus on two key product areas in the short term (2023-2024) and a number of potential stock catalysts / 短期内(2023-2024)专注于两个主要产品领域，有许多潜在的股价催化剂

Global supply & licensing agreements signed with leading players. / 与一些大型公司签署了全球供应与许可协议

Key Financials First Quarter 2023

/ 2023年第一季度主要财务数据

NYSE American Market: **VNRX**

Market Cap: \$96.1m* / 市值: \$9610万*

52-week range: \$1.22-\$2.74* / 52周价格区间: \$1.22-\$2.74*

Cash used in operating activities: 12-month average ~\$2.4m/mth** / 运营活动使用的现金: 12个月均值为每月约\$240万**

Cash-on-hand: ~\$19.7m** / 手中现金: 约\$1970万**

* As of
Aug 7, 2023 /
截止2023年8月7
日

**As of
June 30, 2023 /
截止2023年6月
30日

Questions? / 问题?

**Thank you for your interest in Volition. /
感谢您关注Volition**

**For more details, please visit www.volition.com /
欲了解更多信息，请访问网站www.volition.com**

The Team

团队

Executive Team



Dill Faulkes PhD, Executive Chairman - Dill Faulkes has over 30 years of entrepreneurial and managerial experience as the founder and CEO of several software companies within the United Kingdom and the United States. As the Founder and one of the Benefactors of the Dill Faulkes Educational Trust, a UK registered charity, Dill also focuses on charitable activities.



Cameron Reynolds MBA, President & Group Chief Executive Officer - Cameron has extensive experience in the management, structuring, and strategic planning of start-up companies and has held positions including Chief Executive Officer, Chief Financial Officer, and Non-Executive Director of public and private enterprises. Cameron was educated at the University of Western Australia receiving both a B.Com. and an MBA.



Terig Hughes, Group Chief Financial Officer – Terig is a seasoned finance professional with over twenty-five years of accounting, finance and business management experience gained through an international career spanning US, Europe and Asia. Terig received a Bachelor's degree in Accounting and Law from De Montfort University, Leicester, UK.



Gaetan Michel PhD, Chief Operating Officer – Gaetan has over 15 years' project management, manufacturing and operational experience at AAT (Advanced Array Technology), EAT (Eppendorf Array Technology), KitoZyme a global manufacturer of biopolymers of fungal origin and latterly Volition. Gaetan was educated at the University of Namur, Belgium receiving both a Bachelor of Science and a PhD.



Tom Butera DVM, Chief Executive Officer of VVDD – Tom is a Doctor of Veterinary Medicine with more than 40 years of experience in equine and small animal health in private practice, as well as extensive work in both business development and management of veterinary companies. He earned his Doctor of Veterinary Medicine from the University of Missouri Veterinary School, going on to serve as an Assistant Professor at Tufts University Veterinary School. Tom is an honorary member of the American Veterinary Medical Association and a licensed veterinarian in the Commonwealth of Massachusetts.

高管团队



Dill Faulkes博士，执行董事会主席 - Dill Faulkes作为英国和美国多家软件公司的创始人和首席执行官，拥有超过30年的创业和管理经验。作为英国注册慈善机构Dill Faulkes Educational Trust的创办人和受益人之一，Dill还致力于慈善活动。



Cameron Reynolds，工商管理硕士，总裁兼集团首席执行官 – Cameron在新兴公司的管理，组织和战略规划方面拥有丰富的经验，并在公共和私营企业担任首席执行官、首席财务官以及非执行董事。Cameron在西澳大利亚大学获得商学学士和工商管理硕士学位。



Terig Hughes，集团首席财务官 – Terig是一位经验丰富的财务专家，拥有超过25年的会计、财务和商业管理经验，其国际职业生涯横跨美国、欧洲和亚洲，在英国莱斯特的德蒙福特大学获得了会计和法律的学士学位。



Gaetan Michel博士，首席运营官 – Gaetan有超过15年的项目管理、生产和运营经验，曾任职于AAT (先进阵列技术)、EAT (Eppendorf阵列技术)、KitoZyme (全球真菌源生物聚合物制造商)，后来入职Volition，曾在那慕尔大学学习，获得了理学学士和博士学位。



Tom Butera DVM, VVDD首席执行官 – Tom是一名兽医博士，在马匹和小动物健康方面有超过40年的私人执业经验，并在兽医公司的业务发展和管理方面广泛的工作经验，在密苏里大学兽医学院获得了兽医学博士学位，随后在塔夫茨大学兽医学院担任助理教授，是美国兽医协会的荣誉会员，也是马萨诸塞州联邦的执业兽医。

Executive Team



Jake Micallef PhD MBA, Chief Scientific Officer - Jake is an experienced scientist with expertise in research and development and in the management of biotechnical companies, including manufacturing and establishing operations. He received his BSc and a PhD in Physical Chemistry from King's College London. In addition, he received his MSc in Chemical Pathology, and an MBA from Imperial College Management School.



Jasmine Kway PhD, Chief Executive Officer, Singapore Volition - Jasmine has a proven track record in achieving positive business results by developing strategic business alliances and identifying new markets. She has successfully commercialized and expanded companies into the Asian markets. Jasmine has a B.Eng. and a PhD in Oceanography from the National University of Singapore.



Gael Forterre MBA, Chief Commercial Officer - Gael has extensive experience investing in and scaling fast-growing companies, most recently as CEO of Path Inc. He is currently a non-executive board member of Integrated Wellness Holdings. Gael started his career as a hedge fund analyst in Paris and worked in a number of investment banking and more recently executive roles over fifteen plus years. Gael received a master's in finance from Sorbonne Paris I and a double MBA from Columbia Business School and the London Business School.



Louise Batchelor, Group Chief Marketing and Communications Officer - Lou has 30 years of marketing, sales and leadership experience. Formerly Lou worked in various roles at Reckitt Benckiser including roles in Paris and New York and AstraZeneca Pharmaceuticals in the U.K. She holds a BA in Business Studies from Sheffield Hallam University.



Nick Plummer, Group General Counsel - Nick has over 25 years experience as a corporate and commercial lawyer, specializing in healthcare. Nick qualified with the international law firm, Ashurst, and has since worked in-house for companies such as Novacyt, Ark Therapeutics PLC and Patheon, which is part of Thermo Fisher Scientific.



Rodney Rootsart, Corporate Secretary - Rod has been part of the Volition team right from its beginnings in 2011. He is an experienced legal and corporate secretary with over fifteen years' experience in providing corporate, legal and administrative services to start-up companies. He previously served as corporate secretary for several mining companies in the United Kingdom. Rod received a Bachelor of Laws degree from the University of Western Australia.

高管团队



Jake Micallef博士，工商管理硕士，首席科学官 - Jake是一位经验丰富的科学家，在研发和生物技术公司的管理（包括制造和建立运营）方面具有专业知识，获得了伦敦国王学院的理学学士学位和物理化学博士学位，还获得了化学病理学理学硕士学位和帝国大学管理学院的工商管理硕士学位。



Jasmine Kway博士，Singapore Volition首席执行官 - Jasmine在建立积极的商业成果方面有着良好的履历，通过建立战略性商业联盟和确定新市场来取得积极的商业成果。成功地将公司商业化并扩展到亚洲市场。拥有新加坡国立大学的海洋学学士学位和博士学位。



Gael Forterre 工商管理硕士，首席商务官 - Gael在投资和扩大快速增长的公司方面有丰富的经验，最近担任了Path Inc.的首席执行官，目前担任Integrated Wellness Holdings的非执行董事。其职业生涯始于在巴黎担任对冲基金分析师，在15年以上的时间里，曾在多家投资银行工作，后来担任投资银行高管职务。Gael拥有巴黎第一大学的金融硕士学位，以及哥伦比亚商学院和伦敦商学院的双料工商管理硕士学位。



Louise Batchelor，集团首席营销和传播官 - Lou拥有30年的营销、销售和领导经验，曾在Reckitt Benckiser担任过各种职务，包括在巴黎和纽约任职，还曾在英国的AstraZeneca Pharmaceuticals任职，拥有谢菲尔德哈兰大学的商业研究学士学位。



Nick Plummer，集团总法律顾问 - Nick拥有超过25年的企业和商业律师经验，擅长医疗保健领域，在国际律师事务所Ashurst取得资格，此后在企业内部工作，如Novacyt、Ark Therapeutics PLC和Patheon，后者是赛默飞世尔科技的一部分。



Rodney Rootsaert，公司秘书 - Rod于2011年初加入Volition，是一位经验丰富的法律人士和公司秘书，有15年以上为初创公司提供企业、法律和行政服务方面的经验，之前曾在英国的多家矿业公司担任公司秘书。Rod拥有西澳大学法学学士学位。